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Abstract Apolipoprotein E (apoE), a key lipid transport
protein, displays a heparin-binding property that is critical in
several apoE functions. The kinetics of the interaction between
apoE isoforms and glycosaminoglycans (GAGs) were studied
using surface plasmon resonance. The dissociation constant of
equilibrium KD for apoE3-heparin interaction was estimated to
be 12 nM for apoE3 and three common apoE isoforms revealed
similar affinities for heparin. ApoE binds to GAGs in the
following order: heparins heparan sulfates dermatan sulfa-
tes chondroitin sulfate. The affinity parameter of the binding of
low molecular weight heparins to apoE is correlated with the
chain length. The effective number Z of electrostatic interactions
between plasma apoE3 and heparin was assessed to be three.
Metal chelators were able to diminish apoE-binding to heparin,
suggesting some stabilizing effect of metal ions while reconstitu-
tion with lipids did not affect binding affinities for heparin,
suggesting that the N-terminal heparin-binding site is responsible
for apoE-containing lipoprotein interactions with heparin.
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1. Introduction
Apolipoprotein E (apoE) is an important lipid transport
protein in human plasma and brain. It serves as ligand for
several types of receptors, including low density lipoprotein
(LDL) receptor and LDL receptor-related protein (LRP) [1,2].
ApoE also binds to heparin and contains two sites involved in
heparin-binding: a high a⁄nity binding site in the N-terminal
domain and a low a⁄nity binding site in the C-terminal do-
main [3,4]. The heparin-binding property of apoE plays an
important role in the sequestration step of the heparan sulfate
proteoglycan (HSPG)/LRP metabolic pathway as well as in
the independent HSPG pathway [5]. Interactions between lip-
oproteins and proteoglycans are related to the pathogenesis of
atherosclerosis [6,7]. Heparin-binding activity of apoE was
also proposed to be responsible for the inhibitory role of
apoE in cell growth [8]. The human apoE gene has three
common alleles, O2, O3 and O4. Allele O4 has been shown to
be one of the major genetic risk factors of late-onset familial
and sporadic Alzheimer’s disease [9,10] and the mechanism
that involves HSPG was hypothesized [5].
Thus, substantial evidence has been obtained for involving
the heparin-binding activity of apoE in lipid metabolism,
modulation of cell proliferation and atherogenesis. Studies
of the interaction between apoE and extracellular matrix are
particularly important for better understanding the mecha-
nism of atherosclerosis considering the high physiological lev-
el of glycosaminoglycans (GAGs) in the vessel wall. In the
present work, using surface plasmon resonance (SPR) biomo-
lecular interaction analysis (BIA) technology, we studied and
characterized the kinetics of apoE-GAG interactions. SPR is a
biosensor technology that allows us to characterize the ki-
netics of bio-speci¢c interactions under label-free conditions
[11,12].
2. Materials and methods
2.1. Materials and proteins
Sensor chips SA were obtained from Biacore (Sweden). Native hep-
arin, 3 and 6 kDa low molecular weight (LMW) heparins and heparan
sulfate were obtained from Sigma (USA). Dermatan sulfate and chon-
droitin sulfate were purchased from Bioberica, S.A. (Spain). Heparin
pentasaccharide was obtained from Sano¢ (France).
2.2. Puri¢cation of proteins
ApoE3 was puri¢ed from plasma very low density lipoprotein
(VLDL) of individuals with an O3/3 genotype as described [13]. Re-
combinant isoforms apoE2, apoE3 and apoE4 were puri¢ed from
Escherichia coli as described elsewhere [14]. Puri¢ed proteins showed
a single band on polyacrylamide gel electrophoresis in the presence of
sodium dodecyl sulfate [15]. Discoidal apoE/dipalmitoylphosphatidyl-
choline (DPPC) complexes were prepared by a detergent reconstitu-
tion method adapted from [16].
2.3. Biotinylation of GAGs
Heparin, heparan sulfate, dermatan sulfate and chondroitin sulfate
were biotinylated using Biotin-LC-NHS (Pierce, USA) [17]. Five mg
of GAG was dissolved in 2 ml of 50 mM bicarbonate bu¡er, pH 8.5.
Biotinylation was performed in the presence of Biotin-LC-NHS pre-
dissolved in dimethylformamide at a 6:1 GAG:biotin molar ratio to
exclude over-labelling. The mixture was incubated during 1 h at room
temperature, unreacted biotin was removed and the bu¡er was
changed to 25 mM Tris, pH 8.3, by centrifugation on a Centricon-3
(Amicon, USA).
2.4. Immobilization of ligands on sensor chips
SPR experiments were performed on a BIAcore X apparatus (Phar-
macia Biosensor, Sweden). Biotinylated GAG was immobilized on a
streptavidin-pre-coated SA sensor chip by its injection at a concen-
tration of 0.25 mg/ml and at a £ow rate of 5 Wl/min to reach a
saturation of surface.
2.5. SPR experiments
Binding experiments were performed at 25‡C and at a £ow rate of
5 Wl/min as previously described [18]. In most of the experiments, the
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running bu¡er was 10 mM sodium phosphate, 0.15 M NaCl, pH 7.4.
To study the binding of proteins, 20 Wl of analyte in the running
bu¡er was injected over the GAG-coated sensor chip for the associ-
ation phase (contact time 4 min). After 4 min of dissociation, surface
was regenerated by injection of 10 Wl of 1.0 M NaCl in phosphate
bu¡er or 5 Wl of 0.1% sodium dodecyl sulfate. Dissociation and asso-
ciation rates kdiss and kass were calculated by analysis of sensorgrams
with BIAevaluation 2.2.4 software (Biacore, Sweden), using initial
stages of dissociation and association phases, respectively, in accord-
ance to the manufacturer recommendations. Equilibrium dissociation
constant KD was calculated as the ratio of kdiss/kass.
2.6. Other analytical procedures
The protein concentration was measured by the method of Lowry
[19], using bovine serum albumin as the standard.
3. Results
GAGs were immobilized on the surface of a sensor chip
using the streptavidin-biotin system. ApoE was consequently
injected over the immobilized ligand at di¡erent concentra-
tions to estimate rate constants and a⁄nity parameters of
apoE-GAG interactions. We demonstrated that apoE binds
to all studied GAGs (Fig. 1). Among studied GAGs, apoE
demonstrated the highest binding to heparin, whereas its bind-
ing to chondroitin sulfate was the lowest. The following order
of apoE-binding was observed: heparins heparan sulfa-
tes dermatan sulfates chondroitin sulfate. The di¡erences
found between GAGs in the binding to apoE were particu-
larly due to increased dissociation of the protein from derma-
tan sulfate and chondroitin sulfate (Table 1).
Pre-incubation of apoE with GAG inhibited its binding
activity, revealed by following injection over heparin- or hep-
aran sulfate-coated sensor chip. The same order of GAG-
binding a⁄nities towards apoE was demonstrated by compe-
tition with heparin (Fig. 2A) and heparan sulfate (data not
shown). Heparin in an equimolar ratio (1:1) completely
blocked binding of apoE to heparan sulfate.
Furthermore, we investigated possible isoform-speci¢c in-
teractions of apoE to heparin. The heparin-binding property
of recombinant apoE3 was actually equal to apoE3 isolated
from plasma with a KD of 13 and 12 nM, respectively. Three
common apoE isoforms, apoE2, apoE3 and apoE4, demon-
strated a similar a⁄nity parameter of the binding with an
equilibrium dissociation constant KD of 15.6 þ 1.8, 13.4 þ 2.6
and 12.2 þ 3.0 nM, respectively (n = 6).
E¡ects of the heparin chain length on its interaction with
apoE were studied in competition experiments. Binding of
apoE to heparin-coated surface was reduced by pre-incuba-
tion of the protein with free fragments of heparin. Both 6 and
3 kDa LMW heparins as well as pentamer showed this e¡ect.
The a⁄nity parameter of the fragments negatively correlated
with the chain length (Fig. 2B). Data demonstrate that the
pentamer still has a su⁄cient number of monomers to be able
to interact with the protein.
The interaction between apoE and heparin is highly electro-
static and depends on the salt concentration [20]. In accord-
ance to the molecular theory of polyelectrolyte solutions, the
reaction between the protein and polyelectrolyte chain may be
described as a ion-exchange process [21]. In the frames of the
theory, the e¡ect of the concentration of a monovalent cation
on protein-polyelectrolyte interaction is described by the fol-
lowing equation:
log KD  log K 03Zi log M
where KD is the equilibrium dissociation constant of the bind-
Fig. 1. Binding of human apoE3 to GAGs. Biotinylated GAGs were immobilized on SA sensor chip. Forty Wl of apoE3 was injected over the
sensor chip in 10 mM phosphate-bu¡ered saline (PBS), pH 7.4. SPR analysis was performed at a £ow rate of 5 Wl/min at 25‡C. Shown traces
correspond to a apoE concentration of 1.0 WM.
Table 1
Binding of human plasma apoE3 to GAGs
GAG kass, M31 s31 kdiss, s31 KD, nM
Heparin 1.90U1034 þ 0.65U1034 2.19U104 þ 0.53U104 11.5
Heparan sulfate 2.36U1034 þ 0.35U1034 2.90U104 þ 0.86U104 12.3
Dermatan sulfate 2.28U1034 þ 0.22U1034 4.58U104 þ 0.87U104 20.1
Chondroitin sulfate 2.02U1034 þ 0.42U1034 6.12U104 þ 0.14U104 30.3
Mean þ S.D. are shown (n = 6).
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ing, K0 is a constant re£ecting the contribution of non-elec-
trostatic interaction, Z is a number of ionic interactions, i is
the axial charge density of polyelectrolyte, [M] is the concen-
tration of a monovalent ion. The a⁄nity of apoE3-heparin
interaction was determined as a function of the salt concen-
tration. We found a linear dependency of log KD on log [M]
(Fig. 3) and the slope was calculated as 2.2. Considering the
axial charge density of heparin to be i= 0.7 [22], the number
of ionic interactions between apoE and heparin was deter-
mined to be 3.1.
We then studied the e¡ects of Ca2 on apoE-binding to
heparin. The presence of 1 mM CaCl2 had no e¡ects on the
interaction (Fig. 4). In contrast, the addition of 1 mM ethyl-
enediaminetetraacetic acid (EDTA) reduced the binding par-
ticularly due to increasing the dissociation rate. Similar e¡ects
were observed after the addition of another metal chelator,
diethylenetriaminepentaacetic acid (DETAPAC).
To study the e¡ects of lipid on the apoE-binding activity,
the protein was reconstituted with DPPC to form discoidal
apoE-lipid particles. Preliminary experiments showed that to
Fig. 2. Competition of GAGs (A) and LMW heparins (B) with native heparin for the binding to apoE. Native heparin was immobilized on SA
sensor chip. ApoE was pre-incubated with an equimolar concentration of heparin competitor in 10 mM PBS and 40 Wl of the mixture was in-
jected over the heparin-coated surface at a £ow rate of 5 Wl/min. Shown traces correspond to an apoE concentration of 1.0 WM.
Fig. 3. Dependence of the KD of apoE3-binding to heparin on the
salt concentration. The dissociation constant of equilibrium was
measured in 10 mM phosphate bu¡er, pH 7.4, and a varied salt
concentration.
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obviate mass transport limitations, the £ow rate had to be
increased to 30 Wl/min and the binding of apoE/DPPC com-
plexes to heparin was studied under these conditions (Fig. 5).
The equilibrium dissociation constant KD of apoE3/DPPC-
binding to heparin was calculated to be 7 nM and was close
to that of free apoE.
4. Discussion
Recent studies increasingly implicate proteoglycans as scaf-
fold structures designed to accommodate proteins through
non-covalent binding to their GAG side chains [23]. Binding
to proteoglycans, particularly to HSPG, is a prerequisite to
reveal their biological or pathophysiological activities for sev-
eral important proteins of lipid metabolism, including lipo-
protein lipase, hepatic lipase, apoB and apoE [5,24,25].
Some HSPGs, syndecans and perlecans, are also able to di-
rectly mediate the internalization of lipoproteins [26].
In the present work, we characterized the kinetics of apoE
interaction with heparin and major GAGs of the extracellular
matrix. We measured the dissociation constant of equilibrium
of human apoE3 interaction with heparin KD as 12 nM. Other
common apoE isoforms showed close a⁄nities. Apparently,
the binding to heparin does not depend on some variability of
apoE conformation likely due to £exibility of the GAG chain.
Comparison of di¡erent GAGs revealed the following order
of binding a⁄nities for apoE: heparins heparan sulfa-
tes dermatan sulfates chondroitin sulfate. Observed di¡er-
ences may be explained by the higher dissociation rate of
dermatan sulfate and chondroitin sulfate from apoE. Appa-
rently, these GAGs lack charged groups that stabilize the
apoE-ligand complex as compared to highly sulfated heparin
and heparan sulfate chains. Earlier, it has been demonstrated
that extensively sulfated GAGs bind apoE-containing emul-
sions with high a⁄nity in contrast to low-sulfated dermatan
sulfate and chondroitin sulfate [27]. A heparin/heparinase-re-
leasable pool of apoE on the HepG2 cell surface has previ-
ously been described [28,29]. Recently, chondroitin sulfate
proteoglycans were shown to be the main site of apoE cell
surface pool deposition in these cells along with HSPG [30].
Fig. 4. E¡ects of Ca2 and EDTA on apoE-binding to heparin. Heparin was immobilized on SA sensor chip. An apoE-binding assay was per-
formed in 10 mM Tris-HCl, pH 7.4 (curve 1), in the presence of 1 mM CaCl2 (curve 2) or 1 mM EDTA (curve 3). Traces shown correspond
to injections of apoE3 at a concentration of 1.0 WM.
Fig. 5. E¡ects of lipid on apoE-binding to heparin. An apoE-binding assay was performed in 10 mM PBS, pH 7.4. Thirty Wl of apoE3/DPPC
complex preparation was injected at a £ow rate of 30 Wl/min over heparin-coated sensor chip. Concentrations of apoE were varied from 1.0 to
0.25 WM as shown to the right of traces.
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Our data suggest that all three major GAGs of the extracel-
lular matrix should be able to detain apoE on the cell surface.
However, the pathophysiological importance of apoE-binding
to dermatan sulfate and chondroitin sulfate still remains to be
elucidated.
Furthermore, we estimated the ability of short-chain hepa-
rins to compete with heparin for apoE-binding. Despite di-
minished binding to apoE, LMW heparins were able to inhibit
apoE interaction with native heparin. Pentamer demonstrated
the lowest a⁄nity among studied heparin fragments. It has
generally been assumed that the major interactions between
proteins and GAGs are electrostatic and involve the nega-
tively charged sulfates and carboxylates on the GAG and
positively charged residues on the protein [20]. The number
of ionic interactions between apoE and heparin was calculated
to be about three. Earlier, the number of electrostatic forces
between lipoprotein lipase and heparin was determined to be
about 10 [31]. This di¡erence likely explains a higher a⁄nity
of the lipoprotein lipase-heparan sulfate interaction with
KD = 0.3 nM as compared to apoE. For example, addition
of lipoprotein lipase to apoE-containing L-VLDL increases
lipoprotein-binding a⁄nity for HSPG 12^55-fold [32].
It has been proposed that apoE can bind metal ions as the
protein is able to modulate the kinetics of the metal-induced
lipoprotein oxidation and aggregation of L-amyloid [33,34].
Moreover, it was demonstrated on HepG2 cells that EDTA
or ethylenebis(oxyethylenenitrilo)tetraacetic acid are able to
displace part of the cell surface-associated pool of apoE,
which binds to extracellular matrix via HSPG or other matrix
elements, suggesting that the mechanism of the interaction
may be Ca2-dependent [35]. Thus, we studied the e¡ects of
Ca2 on apoE-binding to heparin. While the presence of 1 mM
Ca2 did not change the KD of the interaction, metal chelators
such as EDTA and DETAPAC increased dissociation of
the complex. The data indicate that metal ions are not
critical in the binding but that they are likely able to stabilize
apoE-heparin complex. We suggested that trace bivalent cat-
ions may partially stabilize apoE-GAG complex, serving as
non-speci¢c ionic bridge(s). Interestingly, several GAGs were
found to suppress Cu2-induced oxidation of VLDL apoE
and the e¡ects did not depend on their chelator activities
[36]. However, possible metal-speci¢c e¡ects other than
Ca2 on apoE-GAG interaction remain to be elucidated.
Two heparin-binding sites of apoE were identi¢ed and char-
acterized [3]. The C-terminal heparin-binding site is exposed
only in lipid-free apoE. In this work, we found that apoE
reconstituted with lipid exhibits a⁄nity for heparin close to
that of the free protein. Thus, it might be suggested that the
high a⁄nity binding site of apoE localized in the N-terminal
domain and exposed in lipoproteins is the most important for
apoE-binding to heparin.
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